Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort stud
9 hours ago
- #Non-small-cell lung cancer
- #Immunotherapy
- #Survival analysis
- Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy (NICT) and pembrolizumab with chemotherapy (PCT) in advanced non-small cell lung cancer (NSCLC).
- Study involved 457 patients across 13 institutions in Japan from 2019 to 2022, stratified by PD-L1 tumor proportion score (TPS).
- NICT showed significantly longer overall survival (OS) than PCT in PD-L1 TPS < 1% patients (median 47.4 vs. 16.6 months).
- No significant OS differences between regimens in PD-L1 TPS ≥ 1% patients.
- Comparable rates of grade ≥ 3 treatment-related adverse events (TRAEs), discontinuation, and death between NICT and PCT.
- NICT may be a promising option for PD-L1 negative advanced NSCLC with sustained long-term survival benefits.